A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
KINDLE
A Multi-country, Multi-centre, Observational, Retrospective Study to Reveal the Patient Characteristics, Disease Burden, Treatment Patterns and Patient Journey of Stage III Non-small-cell Lung Cancer Patients
1 other identifier
observational
3,111
10 countries
32
Brief Summary
This large multinational, non-interventional study (NIS), will retrospectively collect data derived from established medical records over a period of up to approximately 6 years (2013 to 2018), building a platform to capture and consolidate information on treatment patterns, Overall Survival (OS) and treatment effectiveness outcomes in the real-world setting.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2018
Shorter than P25 for all trials
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 22, 2018
CompletedFirst Posted
Study publicly available on registry
October 31, 2018
CompletedStudy Start
First participant enrolled
November 26, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2019
CompletedOctober 5, 2020
September 1, 2020
10 months
October 22, 2018
October 1, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival (OS)
The length of time from stage III NSCLC diagnosis (index date) or time of therapy initiation to death due to any cause.
Up to 5 years
Secondary Outcomes (1)
Progression-free survival (PFS)
Up to 5 years
Other Outcomes (1)
Time to progression (TTP)
Up to 5 years
Study Arms (1)
Stage III
stage III Non-small Cell Lung Cancer (NSCLC )
Eligibility Criteria
stage III non-small-cell lung cancer patients
You may qualify if:
- Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations
- Adult male or female (≥18 years old or according to age of majority as defined by local regulations)
- First ever diagnosis of lung cancer (absence of previous diagnosis of lung cancer, including small cell lung cancer \[SCLC\] and NSCLC) in the patient's medical records
- Primary diagnosis of stage III NSCLC, confirmed by pathology, between 01 January 2013 and 31 December 2017
- Available medical records
You may not qualify if:
- Patients with a concomitant cancer at the time of diagnosis of stage III NSCLC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms. A cancer will be considered concomitant if it occurs within 5 years of NSCLC diagnosis
- Patients initially diagnosed with stage I-II NSCLC who have progressed to stage III
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (32)
Research Site
Buenos Aires, Argentina
Research Site
Rosario, Argentina
Research Site
Santiago, Chile
Research Site
Cali, Colombia
Research Site
Córdoba, Colombia
Research Site
Medellín, Colombia
Research Site
Santo Domingo, Dominican Republic
Research Site
Anand, India
Research Site
Bangalore, India
Research Site
Calicut, India
Research Site
Chennai, India
Research Site
Mohali, India
Research Site
Mumbai, India
Research Site
Nashik, India
Research Site
New Delhi, India
Research Site
Odissa, India
Research Site
Srinagar, India
Research Site
West Bengal, India
Research Site
Guadalajara, Mexico
Research Site
Mexico City, Mexico
Research Site
Toluca, Mexico
Research Site
Lima, Peru
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan District, Taiwan
Research Site
Bangkoknoi, Thailand
Research Site
Dusit, Thailand
Research Site
Pathumwan, Thailand
Research Site
Ratchathewi, Thailand
Research Site
Montevideo, Uruguay
Related Publications (3)
Aboelhassan R, Sobeih ME, El-Din MA, Ghali RR, El-Din IS, Khorshid O, Mokhtar M, Rabea AM, Belal A, Azim HA, Abdullah M, Elnahas T, Tawfik H, Abdelwahab S, Elsaid AA, Hashem T, Mancy M, Farag H. Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort. Ther Adv Med Oncol. 2023 Nov 22;15:17588359231212182. doi: 10.1177/17588359231212182. eCollection 2023.
PMID: 38028146DERIVEDJazieh AR, Onal HC, Tan DS, Soo RA, Prabhash K, Kumar A, Huggenberger R, Cho BC. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study. Ther Adv Med Oncol. 2022 Sep 12;14:17588359221122720. doi: 10.1177/17588359221122720. eCollection 2022.
PMID: 36119641DERIVEDMartin CM, Puello-Guerrero A, Mas-Lopez LA, Campos-Gomez S, Orlando-Orlandi FJ, Tejado Gallegos LF, Huggenberger R. Real-world KINDLE-Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non-small-cell lung cancer. Cancer Med. 2023 Jan;12(2):1247-1259. doi: 10.1002/cam4.4990. Epub 2022 Jul 4.
PMID: 35789068DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 22, 2018
First Posted
October 31, 2018
Study Start
November 26, 2018
Primary Completion
September 30, 2019
Study Completion
September 30, 2019
Last Updated
October 5, 2020
Record last verified: 2020-09